Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer

GP Sawiris, CA Sherman-Baust, KG Becker, C Cheadle… - Cancer Research, 2002 - AACR
GP Sawiris, CA Sherman-Baust, KG Becker, C Cheadle, D Teichberg, PJ Morin
Cancer Research, 2002AACR
Ovarian cancer is a major cause of cancer death in women. Unfortunately, the molecular
pathways underlying ovarian cancer progression are poorly understood, making the
development of novel diagnostic and therapeutic strategies difficult. On the basis of our
previous observations obtained from serial analysis of gene expression, we have
constructed a specialized cDNA array for the study of ovarian cancer. Small, specialized
arrays have several practical advantages and can reveal information that is lost in the …
Abstract
Ovarian cancer is a major cause of cancer death in women. Unfortunately, the molecular pathways underlying ovarian cancer progression are poorly understood, making the development of novel diagnostic and therapeutic strategies difficult. On the basis of our previous observations obtained from serial analysis of gene expression, we have constructed a specialized cDNA array for the study of ovarian cancer. Small, specialized arrays have several practical advantages and can reveal information that is lost in the “noise” generated by irrelevant genes present in larger arrays. The array, which we named Ovachip, contains 516 cDNAs chosen from our serial analysis of gene expression and cDNA array studies for their relevance to ovarian cancer. The gene expression patterns revealed with the Ovachip are highly reproducible and extremely consistent among the different ovarian specimens tested. This array was extremely sensitive at differentiating ovarian cancer from colon cancer based on expression profiles. The Ovachip revealed clusters of coordinately expressed genes in ovarian cancer. One such cluster, the IGF2 cluster, is particularly striking and includes the insulin-like growth factor II, the cisplatin resistance-associated protein, the checkpoint suppressor 1, the cyclin-dependent kinase 6, and a protein tyrosine phosphatase receptor. We also identified a cluster of down-regulated genes that included the cyclin-dependent kinase 7 and cyclin H. Thus, the Ovachip allowed us to identify previously unidentified clusters of differentially expressed genes that may provide new paradigms for molecular pathways important in ovarian malignancies. Because of the relevance of the arrayed genes, the Ovachip may become a powerful tool for investigators in the field of ovarian cancer and may facilitate progress in understanding the etiology of this disease and in its clinical management.
AACR